P
US7012134B2ExpiredUtilityPatentIndex 93

Dendritic enriched secreted lymphocyte activation molecule

Assignee: HUMAN GENOME SCIENCES INCPriority: Jan 26, 1998Filed: Feb 5, 2002Granted: Mar 14, 2006
Est. expiryJan 26, 2018(expired)· nominal 20-yr term from priority
Inventors:RUBEN STEVEN MYOUNG PAUL E
A61K 2039/5154C07K 2319/30C07K 14/47C07K 2319/00A01K 2217/05A61K 48/00A01K 2217/075A61K 38/00C12N 2799/026C07K 14/70596
93
PatentIndex Score
38
Cited by
30
References
93
Claims

Abstract

The present invention relates to a novel human protein called Dendritic Enriched Secreted Lymphocyte Activation Molecule, and isolated polynucleotides encoding this protein. Also provided are vectors, host cells, antibodies, and recombinant methods for producing this human protein. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to this novel human protein.

Claims

exact text as granted — not AI-modified
1. An isolated antibody or fragment thereof that specifically binds to a protein selected from the group consisting of:
 (a) a protein consisting of amino acid residues 1 to 285 of SEQ ID NO:2;  
 (b) a protein consisting of amino acid residues 23 to 285 of SEQ ID NO:2;  
 (c) a protein consisting of amino acid residues 23 to 232 of SEQ ID NO:2;  
 (d) a protein consisting of a portion of SEQ ID NO:2, wherein said portion is at least 30 contiguous amino acid residues of SEQ ID NO:2 in length; and  
 (e) a protein consisting of a portion of SEQ ID NO:2, wherein said portion is at least 50 contiguous amino acid residues of SEQ ID NO:2 in length.  
 
     
     
       2. The antibody or fragment thereof of  claim 1  that specifically binds protein (a). 
     
     
       3. The antibody or fragment thereof of  claim 1  that specifically binds protein (b). 
     
     
       4. The antibody or fragment thereof of  claim 1  that specifically binds protein (c). 
     
     
       5. The antibody or fragment thereof of  claim 1  that specifically binds protein (d). 
     
     
       6. The antibody or fragment thereof of  claim 1  that specifically binds protein (e). 
     
     
       7. The antibody or fragment thereof of  claim 2  that specifically binds protein (b). 
     
     
       8. The antibody or fragment thereof of  claim 4  wherein said protein bound by said antibody or fragment thereof is glycosylated. 
     
     
       9. The antibody or fragment thereof of  claim 4  which is a human antibody. 
     
     
       10. The antibody or fragment thereof of  claim 4  which is a polyclonal antibody. 
     
     
       11. The antibody or fragment thereof of  claim 4  which is selected from the group consisting of:
 (a) a chimeric antibody;  
 (b) a humanized antibody;  
 (c) a single chain antibody; and  
 (d) a Fab fragment.  
 
     
     
       12. The antibody or fragment thereof of  claim 4  which is coupled or conjugated to a detectable substance. 
     
     
       13. The antibody of fragment thereof of  claim 12  wherein the detectable substance is selected from the group consisting of:
 (a) an enzyme;  
 (b) a fluorescent label;  
 (c) a luminescent label;  
 (d) a bioluminescent label;  
 (e) a radioactive label; and  
 (f) a prosthetic label.  
 
     
     
       14. The antibody or fragment thereof of  claim 4  wherein said antibody or fragment thereof specifically binds to said protein in a Western blot. 
     
     
       15. The antibody or fragment thereof of  claim 4  wherein said antibody or fragment thereof specifically binds to said protein in an ELISA. 
     
     
       16. An isolated cell that produces the antibody or fragment thereof of  claim 4 . 
     
     
       17. A hybridoma that produces the antibody or fragment thereof of  claim 4 . 
     
     
       18. A method of detecting a protein in a biological sample comprising:
 (a) contacting the biological sample with the antibody or fragment thereof of  claim 4 ; and  
 (b) detecting the protein in the biological sample.  
 
     
     
       19. The method of  claim 18  wherein the antibody or fragment thereof is a polyclonal antibody. 
     
     
       20. An isolated antibody or fragment thereof obtained from an animal that has been immunized with a protein selected from the group consisting of:
 (a) a protein consisting of amino acid residues 1 to 285 of SEQ ID NO:2;  
 (b) a protein consisting of amino acid residues 23 to 285 of SEQ ID NO:2;  
 (c) a protein consisting of amino acid residues 23 to 232 of SEQ ID NO:2;  
 (d) a protein consisting of a portion of SEQ ID NO:2, wherein said portion is at least 30 contiguous amino acid residues of SEQ ID NO:2 in length; and  
 (e) a protein consisting of a portion of SEQ ID NO:2, wherein said portion is at least 50 contiguous amino acid residues of SEQ ID NO:2 in length;  
 wherein said antibody or fragment thereof specifically binds to said amino acid sequence.  
 
     
     
       21. The antibody or fragment thereof of  claim 20  obtained from an animal immunized with protein (a). 
     
     
       22. The antibody or fragment thereof of  claim 20  obtained from an animal immunized with protein (b). 
     
     
       23. The antibody or fragment thereof of  claim 20  obtained from an animal immunized with protein (c). 
     
     
       24. The antibody or fragment thereof of  claim 20  obtained from an animal immunized with protein (d). 
     
     
       25. The antibody or fragment thereof of  claim 20  obtained from an animal immunized with protein (e). 
     
     
       26. The antibody or fragment thereof of  claim 20  which is a monoclonal antibody. 
     
     
       27. The antibody or fragment thereof of  claim 20  which is selected from the group consisting of:
 (a) a chimeric antibody;  
 (b) a polyclonal antibody;  
 (c) a humanized antibody;  
 (d) a single chain antibody; and  
 (e) a Fab fragment.  
 
     
     
       28. An isolated monoclonal antibody or fragment thereof that specifically binds to a protein selected from the group consisting of:
 (a) a protein consisting of amino acid residues 1 to 285 of SEQ ID NO:2;  
 (b) a protein consisting of amino acid residues 23 to 285 of SEQ ID NO:2;  
 (c) a protein consisting of amino acid residues 23 to 232 of SEQ ID NO:2;  
 (d) a protein consisting of a portion of SEQ ID NO:2, wherein said portion is at least 30 contiguous amino acid residues of SEQ ID NO:2 in length; and  
 (e) a protein consisting of a portion of SEQ ID NO:2, wherein said portion is at least 50 contiguous amino acid residues of SEQ ID NO:2 in length.  
 
     
     
       29. The antibody or fragment thereof of  claim 28  that specifically binds protein (a). 
     
     
       30. The antibody or fragment thereof of  claim 28  that specifically binds protein (b). 
     
     
       31. The antibody or fragment thereof of  claim 28  that specifically binds protein (c). 
     
     
       32. The antibody or fragment thereof of  claim 28  that specifically binds protein (d). 
     
     
       33. The antibody or fragment thereof of  claim 28  that specifically binds protein (e). 
     
     
       34. The antibody or fragment thereof of  claim 29  that specifically binds protein (b). 
     
     
       35. The antibody or fragment thereof of  claim 31  wherein said protein bound by said antibody or fragment thereof is glycosylated. 
     
     
       36. The antibody or fragment thereof of  claim 31  which is a human antibody. 
     
     
       37. The antibody or fragment thereof of  claim 31  which is selected from the group consisting of:
 (a) a chimeric antibody;  
 (b) a humanized antibody;  
 (c) a single chain antibody; and  
 (d) a Fab fragment.  
 
     
     
       38. The antibody or fragment thereof of  claim 31  which is coupled or conjugated to a detectable substance. 
     
     
       39. The antibody or fragment thereof of  claim 38  wherein the detectable substance is selected from the group consisting of:
 (a) an enzyme;  
 (b) a fluorescent label;  
 (c) a luminescent label;  
 (d) a bioluminescent label;  
 (e) a radioactive label; and  
 (f) a prosthetic label.  
 
     
     
       40. The antibody or fragment thereof of  claim 31  wherein said antibody or fragment thereof specifically binds to said protein in a Western blot. 
     
     
       41. The antibody or fragment thereof of  claim 31  wherein said antibody or fragment thereof specifically binds to said protein in an ELISA. 
     
     
       42. An isolated cell that produces the antibody or fragment thereof of  claim 31 . 
     
     
       43. A hybridoma that produces the antibody or fragment thereof of  claim 31 . 
     
     
       44. A method of detecting a protein in a biological samples comprising:
 (a) contacting the biological sample with the antibody or fragment thereof of  claim 31 ; and  
 (b) detecting the protein in the biological sample.  
 
     
     
       45. An isolated antibody or fragment thereof that specifically binds to a protein selected from the group consisting of:
 (a) a protein consisting of the full-length polypeptide encoded by the cDNA contained in ATCC Deposit Number 209623;  
 (b) a protein consisting of a portion of the polypeptide encoded by the cDNA contained in ATCC Deposit Number 209623, wherein said portion is at least 30 contiguous amino acid residues in length of the polypeptide encoded by the cDNA contained in ATCC Deposit Number 209623; and  
 (c) a protein consisting of a portion of the polypeptide encoded by the cDNA contained in ATCC Deposit Number 209623, wherein said portion is at least 50 contiguous amino acid residues in length of the polypeptide encoded by the cDNA contained in ATCC Deposit Number 209623.  
 
     
     
       46. The antibody or fragment thereof of  claim 45  that specifically binds protein (a). 
     
     
       47. The antibody or fragment thereof of  claim 45  that specifically binds protein (b). 
     
     
       48. The antibody or fragment thereof of  claim 45  that specifically binds protein (c). 
     
     
       49. The antibody or fragment thereof of  claim 45  wherein said protein bound by said antibody or fragment thereof is glycosylated. 
     
     
       50. The antibody or fragment thereof of  claim 45  which is a human antibody. 
     
     
       51. The antibody or fragment thereof of  claim 45  which is a polyclonal antibody. 
     
     
       52. The antibody or fragment thereof of  claim 45  which is selected from the group consisting of:
 (a) a chimeric antibody;  
 (b) a humanized antibody;  
 (c) a single chain antibody; and  
 (d) a Fab fragment.  
 
     
     
       53. The antibody or fragment thereof of  claim 45  which is coupled or conjugated to a detectable substance. 
     
     
       54. The antibody or fragment thereof of  claim 53  wherein the detectable substance is selected from the group consisting of:
 (a) an enzyme;  
 (b) a fluorescent label;  
 (c) a luminescent label;  
 (d) a bioluminescent label;  
 (e) a radioactive label; and  
 (f) a prosthetic label.  
 
     
     
       55. The antibody or fragment thereof of  claim 45  wherein said antibody or fragment thereof specifically binds to said protein in a Western blot. 
     
     
       56. The antibody or fragment thereof of  claim 45  wherein said antibody or fragment thereof specifically binds to said protein in an ELISA. 
     
     
       57. An isolated cell that produces the antibody or fragment thereof of  claim 45 . 
     
     
       58. A hybridoma that produces the antibody or fragment thereof of  claim 45 . 
     
     
       59. A method of detecting a protein in a biological sample comprising:
 (a) contacting the biological sample with the antibody or fragment thereof of  claim 45 ; and  
 (b) detecting the protein in the biological sample.  
 
     
     
       60. The method of  claim 59  wherein the antibody or fragment thereof is a polyclonal antibody. 
     
     
       61. An isolated antibody or fragment thereof obtained from an animal that has been immunized with a protein selected from the group consisting of:
 (a) a protein consisting of the full-length polypeptide encoded by the cDNA contained in ATCC Deposit Number 209623;  
 (b) a protein consisting of a portion of the polypeptide encoded by the cDNA contained in ATCC Deposit Number 209623, wherein said portion is at least 30 contiguous amino acid residues in length of the polypeptide encoded by the cDNA contained in ATCC Deposit Number 209623; and  
 (c) a protein consisting of a portion of the polypeptide encoded by the cDNA contained in ATCC Deposit Number 209623, wherein said portion is at least 50 contiguous amino acid residues in length of the polypeptide encoded by the cDNA contained in ATCC Deposit Number 209623;  
 wherein said antibody or fragment thereof specifically binds to said amino acid sequence.  
 
     
     
       62. The antibody or fragment thereof of  claim 61  obtained from an animal immunized with protein (a). 
     
     
       63. The antibody or fragment thereof of  claim 61  obtained from an animal immunized with protein (b). 
     
     
       64. The antibody or fragment thereof of  claim 61  obtained from an animal immunized with protein (c). 
     
     
       65. The antibody or fragment thereof of  claim 61  which is a monoclonal antibody. 
     
     
       66. The antibody or fragment thereof of  claim 61  which is selected from the group consisting of:
 (a) a chimeric antibody;  
 (b) a polyclonal antibody;  
 (c) a humanized antibody;  
 (d) a single chain antibody; and  
 (e) a Fab fragment.  
 
     
     
       67. An isolated monoclonal antibody or fragment thereof that specifically binds to a protein selected from the group consisting of:
 (a) a protein consisting of the full-length polypeptide encoded by the cDNA contained in ATCC Deposit Number 209623;  
 (b) a protein consisting of a portion of the polypeptide encoded by the cDNA contained in ATCC Deposit Number 209623, wherein said portion is at least 30 contiguous amino acid residues in length of the polypeptide encoded by the cDNA contained in ATCC Deposit Number 209623; and  
 (c) a protein consisting of a portion of the polypeptide encoded by the cDNA contained in ATCC Deposit Number 209623, wherein said portion is at least 50 contiguous amino acid residues in length of the polypeptide encoded by the cDNA contained in ATCC Deposit Number 209623.  
 
     
     
       68. The antibody or fragment thereof of  claim 67  that specifically binds protein (a). 
     
     
       69. The antibody or fragment thereof of  claim 67  that specifically binds protein (b). 
     
     
       70. The antibody or fragment thereof of  claim 67  that specifically binds protein (c). 
     
     
       71. The antibody or fragment thereof of  claim 67  wherein said protein bound by said antibody or fragment thereof is glycosylated. 
     
     
       72. The antibody or fragment thereof of  claim 67  which is a human antibody. 
     
     
       73. The antibody or fragment thereof of  claim 67  which is selected from the group consisting of:
 (a) a chimeric antibody;  
 (b) a humanized antibody;  
 (c) a single chain antibody; and  
 (d) a Fab fragment.  
 
     
     
       74. The antibody or fragment thereof of  claim 67  which is coupled or conjugated to a detectable substance. 
     
     
       75. The antibody or fragment thereof of  claim 74  wherein the detectable substance is selected from the group consisting of:
 (a) an enzyme;  
 (b) a fluorescent label;  
 (c) a luminescent label;  
 (d) a bioluminescent label;  
 (e) a radioactive label; and  
 (f) a prosthetic label.  
 
     
     
       76. The antibody or fragment thereof of  claim 67  wherein said antibody or fragment thereof specifically binds to said protein in a Western blot. 
     
     
       77. The antibody or fragment thereof of  claim 67  wherein said antibody or fragment thereof specifically binds to said protein in an ELISA. 
     
     
       78. An isolated cell that produces the antibody or fragment thereof of  claim 67 . 
     
     
       79. A hybridoma that produces the antibody or fragment thereof of  claim 67 . 
     
     
       80. A method of detecting a protein in a biological sample comprising:
 (a) contacting the biological sample with the antibody or fragment thereof of  claim 67 ; and  
 (b) detecting the protein in the biological sample.  
 
     
     
       81. An isolated antibody or fragment thereof that specifically binds Dendritic Enriched Secreted Lymphocyte Activation Molecule protein purified from a cell culture wherein the cells in said cell culture comprise a polynucleotide encoding amino acids 23 to 232 of SEQ ID NO:2 operably associated with a regulatory sequence that controls the expression of said polynucleotide. 
     
     
       82. The antibody or fragment thereof of  claim 81  which is a monoclonal antibody. 
     
     
       83. The antibody or fragment thereof of  claim 81  which is a human antibody. 
     
     
       84. The antibody or fragment thereof of  claim 81  which is selected from the group consisting of:
 (a) a chimeric antibody;  
 (b) a polyclonal antibody;  
 (c) a humanized antibody;  
 (d) a single chain antibody; and  
 (e) a Fab fragment.  
 
     
     
       85. The antibody or fragment thereof of  claim 81  wherein said antibody or fragment thereof binds to said protein in a Western blot. 
     
     
       86. The antibody or fragment thereof of  claim 81  wherein said antibody or fragment thereof binds to said protein in an ELISA. 
     
     
       87. An isolated antibody or fragment thereof that binds a protein comprising amino acid residues 23 to 232 of SEQ ID NO:2 with a dissociation constant (KD) less than or equal to 10 −8  M. 
     
     
       88. The isolated antibody or fragment thereof of  claim 87 , wherein the isolated antibody or fragment has a dissociation constant (KD) less than or equal to 10 −9  M. 
     
     
       89. The isolated antibody or fragment thereof of  claim 87 , wherein the isolated antibody or fragment has a dissociation constant (KD) less than or equal to 10 −10  M. 
     
     
       90. The isolated antibody or fragment thereof of  claim 87 , wherein the isolated antibody or fragment has a dissociation constant (KD) less than or equal to 10 −11  M. 
     
     
       91. The isolated antibody or fragment thereof of  claim 87 , wherein the isolated antibody or fragment has a dissociation constant (KD) less than or equal to 10 −12  M. 
     
     
       92. The antibody or fragment thereof of  claim 87 , wherein said protein bound by said antibody or fragment thereof is glycosylated. 
     
     
       93. The antibody or fragment thereof of  claim 87  which is a human antibody.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.